Answers are grounded in this paper and cite their sources.
We report one of the first cases of eosinophilic gastritis (EoG) in a child under 12 years treated with benralizumab. At 7 years, our patient was started on benralizumab after failing to respond to various combinations of high‐dose omeprazole, milk elimination diet, oral viscous budesonide, and oral systemic steroids. He had a complete depletion of gastrointestinal tissue eosinophils with improved symptoms but had symptomatic flares with tapering of background therapy. However, after 4 years on benralizumab he became symptomatic again. Benralizumab may be a viable option for EoG refractory to systemic steroids but only as a short‐term adjunct therapy. More robust studies with long‐term data are needed, especially in this younger population.
No takes yet. Share an insight, caveat, or question.
Cheung et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: